Coeptis Therapeutics Holdings

Impact: Coeptis Therapeutics Holdings announced positive clinical updates from its CERTAIN-T Phase 1 trial for CER-1236, showing encouraging findings and no dose-limiting toxicities, which could positively impact its stock and future development.

Impact: Coeptis Therapeutics Holdings held its Annual General Meeting where shareholders approved most proposals, re-elected and elected new board members, and approved financial statements. However, a proposal to increase conditional share capital was not approved, which could limit future fundraising flexibility.

Impact: Coeptis Therapeutics Holdings is holding its 2026 Annual General Meeting to discuss key proposals including board elections, financial statements, and an increase in conditional share capital. These decisions will directly affect the company's governance and financial structure.

Impact: Coeptis Therapeutics Holdings is advancing its strategy to secure reimbursement for at-home neurorehabilitation solutions in Europe by enrolling patients in the SwissNeuroRehab and REACT-AVC studies. This move is expected to expand its market reach and revenue streams.